Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 15/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5215585 | 1.00 | LMNA (0.39) | LMNAIRAK4KCNH2PDK2CTSD | |
| SCHEMBL4378117 | 0.91 | IRAK4 (0.37) | LMNAIRAK4CTSD | |
| SCHEMBL4378128 | 0.91 | IRAK4 (0.37) | LMNAIRAK4CTSD | |
| SCHEMBL18084625 | 0.83 | IRAK4 (0.40) | IRAK4KCNH2CTSD | |
| SCHEMBL21507384 | 0.83 | IRAK4 (0.40) | IRAK4KCNH2CTSD | |
| SCHEMBL21290423 | 0.83 | IRAK4 (0.40) | IRAK4KCNH2CTSD | |
| SCHEMBL4511068 | 0.81 | IRAK4 (0.33) | IRAK4 | |
| SCHEMBL4511069 | 0.81 | IRAK4 (0.33) | IRAK4 | |
| SCHEMBL21180014 | 0.78 | IRAK4 (0.39) | IRAK4PDK2 | |
| SCHEMBL15727499 | 0.78 | IRAK4 (0.39) | IRAK4PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-04-20 | — | — | US | disclosed |
| EP-2989098-B1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-5066651-A | Sulfonyl group attached to nitrogen, Alzheimer*s disease, antihypoxic, antiischemic, memory lapses | ADIR ET COMPAGNIE (FR) | 1991-11-19 | — | — | US | disclosed |
| US-4113873-A | 8-AZAPROSTANOIC ACID DERIVATIVES | TANABE SEIYAKU CO. LTD. (JP) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | LMNA 2093/4885IRAK4 472/4885KCNH2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.